Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-01-03 4:22 pm Purchase | 2022-12-21 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | Citadel Advisors LLC | 2,682,814 5.500% | 2,682,814 (New Position) | Filing History |
| 2022-12-12 08:41 am Sale | 2022-12-09 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | FMR LLC | 385,863 0.784% | -3,168,232 (-89.14%) | Filing History |
| 2022-07-11 11:51 am Purchase | 2022-06-30 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | STATE STREET CORP STT | 6,776,269 13.930% | 4,204,699 (+163.51%) | Filing History |
| 2022-06-10 11:04 am Sale | 2022-06-09 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | FMR LLC | 3,554,095 7.304% | -3,293,182 (-48.09%) | Filing History |
| 2022-02-14 4:34 pm Sale | 2021-12-31 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | Point72 Asset Management, L.P. | 2,420,309 5.100% | -1,908,721 (-44.09%) | Filing History |
| 2022-02-14 1:57 pm Sale | 2021-12-31 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | Consonance Capital Management LP | 0 0.000% | -2,729,709 (Position Closed) | Filing History |
| 2022-02-14 08:07 am Sale | 2021-12-31 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | RTW INVESTMENTS LP | 2,599,822 5.400% | -1,050,247 (-28.77%) | Filing History |
| 2022-02-11 9:03 pm Purchase | 2021-12-31 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | BIOTECHNOLOGY VALUE FUND L P | 4,891,945 9.990% | 616,980 (+14.43%) | Filing History |
| 2022-02-11 4:18 pm Sale | 2021-12-31 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | FARALLON CAPITAL MANAGEMENT LLC | 3,417,134 6.900% | -507,866 (-12.94%) | Filing History |
| 2022-02-10 3:41 pm Purchase | 2021-12-31 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | STATE STREET CORP STT | 2,571,570 5.390% | 2,571,570 (New Position) | Filing History |
| 2022-02-09 10:24 am Purchase | 2022-02-08 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | FMR LLC | 6,847,277 14.346% | 394,513 (+6.11%) | Filing History |
| 2022-02-02 7:11 pm Purchase | 2021-12-31 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | BlackRock Inc. BLK | 3,281,636 6.900% | 689,925 (+26.62%) | Filing History |
| 2021-09-21 4:34 pm Purchase | 2021-09-20 | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | Point72 Asset Management, L.P. | 4,329,030 9.100% | 4,329,030 (New Position) | Filing History |